|View printer-friendly version|
Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA
Data to highlight recent preclinical studies of SB 11285, a novel next-generation STING agonist
Details of the presentation are as follows:
The conference will highlight recent advances in understanding the range of immune responses towards cancer and how these can be modified and harnessed for prevention and therapeutics. This year’s program will focus on mechanisms, models, and novel technologies all geared towards a deeper understanding of the immunologic science of the cancer cell in order to design better treatments. The conference will take place
Statements in this press release about
For investor inquiries:
Source: Spring Bank Pharmaceuticals Inc.